- Home
- PTGX vs RCKT Comparison
PTGX vs RCKT Comparison
Compare PTGX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | RCKT |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 239.3M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PTGX | RCKT |
|---|---|---|
| Price | $139.52 | $2.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $178.21 | $8.58 |
| AVG Volume (30 Days) | 722.9K | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | ★ 2.35 | 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | $1,077.07 | N/A |
| Revenue Next Year | N/A | $915.60 |
| P/E Ratio | $59.42 | ★ $3.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $74.03 | $2.17 |
| 52 Week High | $160.81 | $5.45 |
Technical Indicators
Market Signals| Indicator | PTGX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 37.77 |
| Support Level | $135.10 | N/A |
| Resistance Level | $142.20 | $3.70 |
| Average True Range (ATR) | 6.12 | 0.18 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 49.12 | 18.70 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.